Recruiting
Early Phase 1

Bimatoprost

Sponsor:

Johns Hopkins University

Code:

NCT03708627

Conditions

Graves Ophthalmopathy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bimatoprost Ophthalmic

Study Details

Brief summary:

Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease

Conditions

Graves Ophthalmopathy

Study ID

NCT03708627

Start date

Nov 1, 2017

Status verified date

Jul, 2026

Completion date

Jul 1, 2031

Anticipated

Primary completion date

Jul 1, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria: Graves' Ophthalmopathy with Exophthalmos/Proptosis -

Exclusion Criteria: Active Graves Disease, Currently pregnant, Taking Steroids

\-

Study Design

Enrollment

3 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Bimatoprost in more proptotic eye

Patients instill Bimatoprost in their more proptotic eye one nightly

no intervention: Control

Bimatoprost is not instilled in the patient's fellow eye

Interventions

Bimatoprost Ophthalmic

Bimatoprost, aka Lumigan, one drop in one eye nightly

Primary outcome measure

  • Reduction in periorbital fat causing improvement in proptosis [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Emily Li, MD

410-955-1112eli20@jhmi.edu

Locations

University of Washington

Recruiting

Seattle, Washington, United States, 98104

Contacts

Alexandra Van Brummen, MD

206-543-7250avanbrum@uw.edu

More Information

Sponsor

Johns Hopkins University

Last update posted

Jul 16, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Johns Hopkins University on 2026-07-16.